Vasodilator and inotropic drugs for the treatment of chronic heart failure: Distinguishing hype from hope

Milton Packer

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

During the past 10 years, more than 80 orally active vasodilator and inotropic agents have been tested in the clinical setting to evaluate their potential utility in the treatment of chronic heart failure. Although the initial reports of all of these drugs suggested that each represented a major therapeutic advance, only three agents-digoxin, captopril and enalapril-have produced consistent longterm hemodynamic and clinical benefits in these severely ill patients. Most of the other drugs that have been tested have not (to date) distinguished themselves from placebo therapy in large-scale, controlled trials, even though these agents produce hemodynamic effects that closely resemble those seen with digitalis and the converting-enzyme inhibitors. These observations suggest that the hemodynamic derangements that characteristically accompany the development of left ventricular dysfunction cannot be considered to be the most important pathophysiologie abnormality in chronic heart failure. Although cardiac contractility is usually depressed in this disease, positive inotropic agents do not consistently improve the clinical status of these patients., Similarly, although the systemic vessels are usually markedly constricted, drugs that ameliorate this vasoconstriction do not consistently relieve symptoms, enhance exercise capacity or prolong life. Hence, correction of the central hemodynamic abnormalities seen in heart failure development, and future advances in therapy are likely to evolve only by attempting to understand and modify the basic physiolosic derangements in this disorder.

Original languageEnglish (US)
Pages (from-to)1299-1317
Number of pages19
JournalJournal of the American College of Cardiology
Volume12
Issue number5
DOIs
StatePublished - 1988

Fingerprint

Hope
Vasodilator Agents
Heart Failure
Hemodynamics
Pharmaceutical Preparations
Enalapril
Digitalis
Digoxin
Captopril
Left Ventricular Dysfunction
Enzyme Inhibitors
Therapeutics
Vasoconstriction
Placebos
Exercise

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Vasodilator and inotropic drugs for the treatment of chronic heart failure : Distinguishing hype from hope. / Packer, Milton.

In: Journal of the American College of Cardiology, Vol. 12, No. 5, 1988, p. 1299-1317.

Research output: Contribution to journalArticle

@article{5a9d9e6a227c41d9bf76833cea56684d,
title = "Vasodilator and inotropic drugs for the treatment of chronic heart failure: Distinguishing hype from hope",
abstract = "During the past 10 years, more than 80 orally active vasodilator and inotropic agents have been tested in the clinical setting to evaluate their potential utility in the treatment of chronic heart failure. Although the initial reports of all of these drugs suggested that each represented a major therapeutic advance, only three agents-digoxin, captopril and enalapril-have produced consistent longterm hemodynamic and clinical benefits in these severely ill patients. Most of the other drugs that have been tested have not (to date) distinguished themselves from placebo therapy in large-scale, controlled trials, even though these agents produce hemodynamic effects that closely resemble those seen with digitalis and the converting-enzyme inhibitors. These observations suggest that the hemodynamic derangements that characteristically accompany the development of left ventricular dysfunction cannot be considered to be the most important pathophysiologie abnormality in chronic heart failure. Although cardiac contractility is usually depressed in this disease, positive inotropic agents do not consistently improve the clinical status of these patients., Similarly, although the systemic vessels are usually markedly constricted, drugs that ameliorate this vasoconstriction do not consistently relieve symptoms, enhance exercise capacity or prolong life. Hence, correction of the central hemodynamic abnormalities seen in heart failure development, and future advances in therapy are likely to evolve only by attempting to understand and modify the basic physiolosic derangements in this disorder.",
author = "Milton Packer",
year = "1988",
doi = "10.1016/0735-1097(88)92615-0",
language = "English (US)",
volume = "12",
pages = "1299--1317",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Vasodilator and inotropic drugs for the treatment of chronic heart failure

T2 - Distinguishing hype from hope

AU - Packer, Milton

PY - 1988

Y1 - 1988

N2 - During the past 10 years, more than 80 orally active vasodilator and inotropic agents have been tested in the clinical setting to evaluate their potential utility in the treatment of chronic heart failure. Although the initial reports of all of these drugs suggested that each represented a major therapeutic advance, only three agents-digoxin, captopril and enalapril-have produced consistent longterm hemodynamic and clinical benefits in these severely ill patients. Most of the other drugs that have been tested have not (to date) distinguished themselves from placebo therapy in large-scale, controlled trials, even though these agents produce hemodynamic effects that closely resemble those seen with digitalis and the converting-enzyme inhibitors. These observations suggest that the hemodynamic derangements that characteristically accompany the development of left ventricular dysfunction cannot be considered to be the most important pathophysiologie abnormality in chronic heart failure. Although cardiac contractility is usually depressed in this disease, positive inotropic agents do not consistently improve the clinical status of these patients., Similarly, although the systemic vessels are usually markedly constricted, drugs that ameliorate this vasoconstriction do not consistently relieve symptoms, enhance exercise capacity or prolong life. Hence, correction of the central hemodynamic abnormalities seen in heart failure development, and future advances in therapy are likely to evolve only by attempting to understand and modify the basic physiolosic derangements in this disorder.

AB - During the past 10 years, more than 80 orally active vasodilator and inotropic agents have been tested in the clinical setting to evaluate their potential utility in the treatment of chronic heart failure. Although the initial reports of all of these drugs suggested that each represented a major therapeutic advance, only three agents-digoxin, captopril and enalapril-have produced consistent longterm hemodynamic and clinical benefits in these severely ill patients. Most of the other drugs that have been tested have not (to date) distinguished themselves from placebo therapy in large-scale, controlled trials, even though these agents produce hemodynamic effects that closely resemble those seen with digitalis and the converting-enzyme inhibitors. These observations suggest that the hemodynamic derangements that characteristically accompany the development of left ventricular dysfunction cannot be considered to be the most important pathophysiologie abnormality in chronic heart failure. Although cardiac contractility is usually depressed in this disease, positive inotropic agents do not consistently improve the clinical status of these patients., Similarly, although the systemic vessels are usually markedly constricted, drugs that ameliorate this vasoconstriction do not consistently relieve symptoms, enhance exercise capacity or prolong life. Hence, correction of the central hemodynamic abnormalities seen in heart failure development, and future advances in therapy are likely to evolve only by attempting to understand and modify the basic physiolosic derangements in this disorder.

UR - http://www.scopus.com/inward/record.url?scp=0023723794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023723794&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(88)92615-0

DO - 10.1016/0735-1097(88)92615-0

M3 - Article

C2 - 2844873

AN - SCOPUS:0023723794

VL - 12

SP - 1299

EP - 1317

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 5

ER -